Gilead Sciences, Inc. $GILD Position Increased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 188,484 shares of the biopharmaceutical company’s stock after buying an additional 4,938 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Gilead Sciences were worth $23,813,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its position in shares of Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC grew its position in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Wilkerson Advisory Group LLC increased its holdings in shares of Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $138.14 on Friday. The stock has a market cap of $171.29 billion, a price-to-earnings ratio of -51.74 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The stock’s 50 day moving average price is $129.93 and its 200 day moving average price is $136.44.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period last year, the company posted $2.01 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s payout ratio is -122.85%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GILD. Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday. Wall Street Zen cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Truist Financial reduced their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Finally, Daiwa Securities Group decreased their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.